Trial · NCT01774786
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
NCT01774786, Phase 3, Completed, Hoffmann-La Roche; results first posted 2018-02-14
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer. Trials, record NCT01774786. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01774786
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- NCT number
- NCT01774786
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 780 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Gastric Cancer
- Interventions
- 5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab
- First posted
- 2013-01-24
- Last updated
- 2020-12-30
- Other registries' IDs
- eudract:2012-003554-83
- Results first posted
- 2018-02-14
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months) | Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day. |
| Secondary | Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria | Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months) | Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions. |
| Secondary | Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria | Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months) | The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan. |
| Secondary | Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria | Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months) | The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan. |
| Secondary | Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria | Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months) | Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan. |
| Secondary | Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria | Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months) | The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis. |
| Secondary | Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03 | From Baseline until end of post-treatment follow-up (up to 70 months) | An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. |
| Secondary | Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD) | From Baseline until end of post-treatment follow-up (up to 70 months) | The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm. |
| Secondary | Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score | Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years) | The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1). |
| Secondary | Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score | Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years) | The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1). |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months) | The intent-to-treat (ITT) population included all randomized participants, regardless of whether study medication was received. | Months | MEDIAN |
| SECONDARY | Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria | Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months) | The ITT population included all randomized participants, regardless of whether study medication was received. | months | MEDIAN |
| SECONDARY | Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria | Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months) | The subset of participants with measurable disease at baseline, according to RECIST v1.1 criteria. | Percentage of participants | NUMBER |
| SECONDARY | Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria | Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months) | The subset of participants with measurable disease at baseline, according to RECIST v1.1 criteria. | Percentage of participants | NUMBER |
| SECONDARY | Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria | Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months) | The participants with measurable disease at baseline who achieved a documented objective response, according to RECIST v1.1 criteria. | months | MEDIAN |
| SECONDARY | Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria | Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months) | The subset of participants with measurable disease at baseline, according to RECIST v1.1 criteria. | percentage of participants | NUMBER |
| SECONDARY | Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03 | From Baseline until end of post-treatment follow-up (up to 70 months) | The safety population included all participants who received any amount of any study medication. Those who received any amount of pertuzumab were included in the pertuzumab arm; all other treated participants were included in the placebo arm. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD) | From Baseline until end of post-treatment follow-up (up to 70 months) | The safety population included all participants who received any amount of any study medication. Those who received any amount of pertuzumab were included in the pertuzumab arm; all other treated participants were included in the placebo arm. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score | Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years) | Participants in the ITT population (includes all randomized participants, regardless of whether study medication was received) with both a baseline assessment and at least 1 post-treatment assessment are included in the analysis. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score | Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years) | Participants in the ITT population (includes all randomized participants, regardless of whether study medication was received) with both a baseline assessment and at least 1 post-treatment assessment are included in the analysis. | score on a scale | MEAN |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 outcomesResults by group1,524
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Pertuzumab + Trastuzumab + Chemotherapy | Primary Analysis | 17.5 | 95% Confidence Interval 16.2 to 19.3 | Months |
| Overall Survival | Placebo + Trastuzumab + Chemotherapy | Primary Analysis | 14.2 | 95% Confidence Interval 12.9 to 15.5 | Months |
| Overall Survival | Pertuzumab + Trastuzumab + Chemotherapy | Final Analysis | 18.1 | 95% Confidence Interval 16.2 to 19.5 | Months |
| Overall Survival | Placebo + Trastuzumab + Chemotherapy | Final Analysis | 14.2 | 95% Confidence Interval 12.9 to 15.7 | Months |
| Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria | Pertuzumab + Trastuzumab + Chemotherapy | Primary Analysis | 8.5 | 95% Confidence Interval 8.2 to 9.7 | months |
| Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria | Placebo + Trastuzumab + Chemotherapy | Primary Analysis | 7.0 | 95% Confidence Interval 6.4 to 8.2 | months |
| Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria | Pertuzumab + Trastuzumab + Chemotherapy | Final Analysis | 8.5 | 95% Confidence Interval 8.3 to 9.7 | months |
| Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria | Placebo + Trastuzumab + Chemotherapy | Final Analysis | 7.2 | 95% Confidence Interval 6.4 to 8.2 | months |
| Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria | Pertuzumab + Trastuzumab + Chemotherapy | Objective Response (CR + PR) | 56.7 | 95% Confidence Interval 51.33 to 61.95 | Percentage of participants |
| Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria | Placebo + Trastuzumab + Chemotherapy | Objective Response (CR + PR) | 48.3 | 95% Confidence Interval 42.97 to 53.65 | Percentage of participants |
1 to 10 of 1,524Source ClinicalTrials.gov
See all 1,524 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pertuzumab + Trastuzumab + Chemotherapy | 388 | |
| Overall Study | STARTED | Placebo + Trastuzumab + Chemotherapy | 392 | |
| Overall Study | Did Not Receive Any Study Treatment | Pertuzumab + Trastuzumab + Chemotherapy | 4 | |
| Overall Study | Did Not Receive Any Study Treatment | Placebo + Trastuzumab + Chemotherapy | 3 | |
| Overall Study | Received at Least One Dose of Pertuzumab | Pertuzumab + Trastuzumab + Chemotherapy | 384 | |
| Overall Study | Received at Least One Dose of Pertuzumab | Placebo + Trastuzumab + Chemotherapy | 1 | |
| Overall Study | Received Placebo (No Pertuzumab) | Pertuzumab + Trastuzumab + Chemotherapy | 0 | |
| Overall Study | Received Placebo (No Pertuzumab) | Placebo + Trastuzumab + Chemotherapy | 388 | |
| Overall Study | COMPLETED | Pertuzumab + Trastuzumab + Chemotherapy | 60 | |
| Overall Study | COMPLETED | Placebo + Trastuzumab + Chemotherapy | 46 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events480
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 159 | 385 | 208 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 142 | 388 | 189 |
| other | Leukopenia | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 80 | 385 | 148 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 69 | 388 | 113 |
| other | Neutropenia | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 200 | 385 | 340 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 202 | 388 | 298 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pertuzumab + Trastuzumab + Chemotherapy | 61 | 385 | 105 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo + Trastuzumab + Chemotherapy | 73 | 388 | 100 |
| other | Abdominal distension | Gastrointestinal disorders | Pertuzumab + Trastuzumab + Chemotherapy | 25 | 385 | 36 |
| other | Abdominal distension | Gastrointestinal disorders | Placebo + Trastuzumab + Chemotherapy | 19 | 388 | 24 |
1 to 10 of 480Source ClinicalTrials.gov
See all 480 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pertuzumab + Trastuzumab + Chemotherapy | 299 | 385 |
| Total, all-cause mortality | Placebo + Trastuzumab + Chemotherapy | 318 | 388 |
| Total, other adverse events | Pertuzumab + Trastuzumab + Chemotherapy | 373 | 385 |
| Total, other adverse events | Placebo + Trastuzumab + Chemotherapy | 376 | 388 |
| Total, serious adverse events | Pertuzumab + Trastuzumab + Chemotherapy | 178 | 385 |
| Total, serious adverse events | Placebo + Trastuzumab + Chemotherapy | 156 | 388 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01774786
GET https://conductscience.org/api/trials/v1/NCT01774786/results?page=2